2023-04-03 08:55:12 ET
- Akebia Therapeutics ( NASDAQ: AKBA ) said that top-line results showed that dosing experimental anemia treatment vadadustat three times weekly met primary and secondary endpoints.
- In the open-label trial, hemodialysis patients were randomized to vadadustat 600mg, vadadustat 900mg, or the long-acting erythropoiesis-stimulating agent Mircera.
- Results showed that vadadustat at both dosages was non-inferior to Mircera.
- The primary endpoint was the mean change in hemoglobin between baseline and the primary evaluation period (weeks 20-26).
- In February, the US FDA issued a second interim response in the company's appeal for lead candidate vadadustat. The agency rejected the drug in 2022 for anemia due to chronic kidney disease.
- Seeking Alpha's Quant Rating has rated Akebia ( AKBA ) a buy since March 16.
For further details see:
Akebia's vadadustat meets endpoints in alternative dosing regimen